Developer finishes FDA application for Friedreich’s ataxia treatment

Larimar expects decision on experimental therapy nomlabofusp by mid-2027

Written by Marisa Horak, MS |

A gloved hand checks a virtual box in front of a row of vials, signifying drug approval.

Larimar Therapeutics has completed an application asking the FDA to approve nomlabofusp, its experimental protein replacement therapy for Friedreich’s ataxia. (Photo from iStock)

Larimar Therapeutics has completed an application asking the U.S. Food and Drug Administration (FDA) to approve nomlabofusp, its experimental protein replacement therapy for Friedreich’s ataxia (FA).

Because nomlabofusp had previously earned certain regulatory designations aimed at speeding its development, Larimar was allowed to do a rolling application – meaning the company could submit sections of the application as soon as they were ready, rather than waiting for the whole thing to be done. Larimar submitted the first section in June, and the company recently announced it had finished the application.

“Completing our BLA [biologics license application] submission is a major milestone for Larimar and the FA community, bringing years of development work together in an application seeking accelerated approval of nomlabofusp,” Carole Ben-Maimon, MD, CEO of Larimar, said in a company press release.

Jen Farmer, CEO of the Friedreich’s Ataxia Research Alliance, said submission of this application “marks an important and exciting milestone for the Friedreich’s ataxia community.”

Larimar said it expects the FDA to accept the completed application for review in early 2027, which would mean a decision could be made by mid-year. If all goes well, Larimar hopes to commercially launch the therapy in the third quarter of 2027.

Recommended Reading
A single DNA is pictured vertically.

Gene editing approach for treating FA shows promise in lab cell models

Nomlabofusp designed to deliver working version of key protein

FA is a genetic disease marked by deficiency of the protein frataxin. Nomlabofusp is an injection treatment designed to deliver a working version of this protein to the body’s cells, thus targeting the underlying cause of FA.

Larimar has asked the FDA to approve nomlabofusp under its accelerated approval pathway, which is a type of conditional approval where the FDA allows a therapy to be brought to market based on early evidence that it will likely benefit patients.

In this case, Larimar is asking the FDA to approve the therapy based on data from an ongoing open-label study (NCT06447025), which showed that the therapy increased frataxin protein levels in participants’ skin cells. Larimar has run animal studies showing that increased frataxin protein levels in skin cells correlate with increased levels in other parts of the body, like the brain and heart.

It is important to note that patients with FA are expected to experience continued neurologic decline, not improvement. After treatment with nomlabofusp, we have not observed worsening in most participants but rather signs of improvement.

Recent data from the open-label study showed that average measures of disease severity improved for up to 1.5 years on nomlabofusp – a notable contrast to the typical progression of FA, where symptoms get worse as time goes on. Larimar said it will provide a new update on data from the open-label study in early 2027.

“Our confidence in the program is grounded in the sustained increases in skin frataxin and consistent directional improvements observed in multiple clinical outcomes in patients,” Ben-Maimon said. “It is important to note that patients with FA are expected to experience continued neurologic decline, not improvement. After treatment with nomlabofusp, we have not observed worsening in most participants but rather signs of improvement.”

Recommended Reading
A group of laboratory mice cluster together, wih one holding a food pellet in its paws.

Regulated gene therapy restores nerve function in Friedreich’s ataxia mice

Confirmatory Phase 3 trial launched

Farmer noted that Larimar’s application includes data from adolescents as young as 12 years old, which “is especially meaningful, as there are currently no approved therapies for children under 16 years of age.”

“FA is a complex and variable disease, and patients and families need multiple treatment options that can address their individual needs across different ages and stages of disease,” Farmer added.

If the FDA decides to grant nomlabofusp accelerated approval, Larimar will be required to run additional testing aimed at definitively confirming whether or not the therapy actually delivers clinical benefit for patients. The company recently launched a Phase 3 trial called FORWARD-FA (NCT07778836), which aims to do just that.

FORWARD-FA is expected to enroll 150 participants, ages 2 to 40 years. Eligible participants will be randomly assigned to receive daily injections of nomlabofusp or a placebo for about 1.5 years, with the main goal of seeing if the therapy slows disease progression as measured with the modified Friedreich’s Ataxia Rating Scale. Enrollment is currently ongoing at four sites in the U.S.

“As we support the potential FDA review and advance FORWARD-FA, our confirmatory Phase 3 study, our team is preparing for a potential U.S. launch with the goal of making nomlabofusp available to patients as quickly as possible following approval, if granted,” Ben-Maimon said. “In parallel, we continue to evaluate options to optimize our global commercialization strategy.”

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.